Growth Metrics

Pfizer (PFE) Goodwill & Intangibles (2016 - 2026)

Pfizer has reported Goodwill & Intangibles over the past 18 years, most recently at $124.0 billion for Q1 2026.

  • Quarterly Goodwill & Intangibles rose 1.26% to $124.0 billion in Q1 2026 from the year-ago period, while the trailing twelve-month figure was $124.0 billion through Mar 2026, up 1.26% year-over-year, with the annual reading at $125.0 billion for FY2025, 0.85% up from the prior year.
  • Goodwill & Intangibles was $124.0 billion for Q1 2026 at Pfizer, down from $125.0 billion in the prior quarter.
  • Over five years, Goodwill & Intangibles peaked at $132.7 billion in Q4 2023 and troughed at $77.6 billion in Q4 2022.
  • The 5-year median for Goodwill & Intangibles is $121.7 billion (2025), against an average of $110.0 billion.
  • Year-over-year, Goodwill & Intangibles surged 41.34% in 2024 and then dropped 7.35% in 2025.
  • A 5-year view of Goodwill & Intangibles shows it stood at $94.7 billion in 2022, then skyrocketed by 40.04% to $132.7 billion in 2023, then decreased by 6.59% to $123.9 billion in 2024, then increased by 0.85% to $125.0 billion in 2025, then fell by 0.82% to $124.0 billion in 2026.
  • Per Business Quant, the three most recent readings for PFE's Goodwill & Intangibles are $124.0 billion (Q1 2026), $125.0 billion (Q4 2025), and $120.4 billion (Q3 2025).